[go: up one dir, main page]

PE20080068A1 - Compuestos derivados de pirimidina como inhibidores de la quinasa aurora - Google Patents

Compuestos derivados de pirimidina como inhibidores de la quinasa aurora

Info

Publication number
PE20080068A1
PE20080068A1 PE2007000569A PE2007000569A PE20080068A1 PE 20080068 A1 PE20080068 A1 PE 20080068A1 PE 2007000569 A PE2007000569 A PE 2007000569A PE 2007000569 A PE2007000569 A PE 2007000569A PE 20080068 A1 PE20080068 A1 PE 20080068A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
inhibitors
aryl
alkyl
pyrimidine
Prior art date
Application number
PE2007000569A
Other languages
English (en)
Inventor
Stephan Karl Zhan
Bojan Bister
Guido Boehmelt
Ulrich Gurtler
Andreas Mantoulidis
Ulrich Reiser
Andreas Schoop
Flavio Solca
Ulrike Tontsch-Grunt
Matthias Treu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37102115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080068(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20080068A1 publication Critical patent/PE20080068A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRIMIDINA DE FORMULA (1) DONDE X ES N O CH; R1 ES CICLOALQUILO(C3-C10) OPCIONALMENTE SUSTITUIDO CON R3 O R4, DONDE R3 ES C(O)Rc, C(O)ORc, S(O)2Rc, ENTRE OTROS, DONDE Rc ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C10), ARILO(C6-C10), ENTRE OTROS; R4 ES Ra O Rb, DONDE Ra ES ALQUILO(C1-C6), CICLOALQUILO(C3-C10), ARILO(C6-C10), ENTRE OTROS; Rb ES =O, HALOALQUILOXI(C1-C3), OCF3, CN, ENTRE OTROS; R2 ES H, HALOGENO, CN, NO2, ALQUILO(C1-C4), ENTRE OTROS; Rg ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C8), ARILO(C6-C10), ENTRE OTROS; m ES 0 O 1; n ES DE 0 A 4; p ES DE 0 A 2. SON COMPUESTOS PREFERIDOS: 4-[4-((1R,2S)-2-ISOPROPILCARBAMOIL-CICLOPENTILAMINO)-5-TRIFLUOROMETIL-PIRIMIDIN-2-ILAMINO]-N-METIL-N-(1,2,2,6,6-PENTAMETIL-PIPERIDIN-4-IL)-BENZAMIDA, N-ISOPROPIL-4-[4-((1R,2S)-2-ISOPROPILCARBAMOIL-CICLOPENTILAMINO)-5-TRIFLUOROMETIL-PIRIMIDIN-2-ILAMINO]-N-(1-METIL-PIPERIDIN-4-IL)-BENZAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA AURORA SIENDO UTILES EN EL TRATAMIENTO DE SARCOMA DE KAPOSI, ARTRITIS, LEUCEMIA, PSORIASIS
PE2007000569A 2006-05-15 2007-05-11 Compuestos derivados de pirimidina como inhibidores de la quinasa aurora PE20080068A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06113967 2006-05-15

Publications (1)

Publication Number Publication Date
PE20080068A1 true PE20080068A1 (es) 2008-03-17

Family

ID=37102115

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007000569A PE20080068A1 (es) 2006-05-15 2007-05-11 Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
PE2011001452A PE20120006A1 (es) 2006-05-15 2007-05-11 Compuestos derivados de pirimidina como inhibidores de la quinasa aurora

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001452A PE20120006A1 (es) 2006-05-15 2007-05-11 Compuestos derivados de pirimidina como inhibidores de la quinasa aurora

Country Status (21)

Country Link
US (1) US8623887B2 (es)
EP (2) EP2027107B1 (es)
JP (1) JP5247681B2 (es)
KR (1) KR20090018955A (es)
CN (1) CN101443325A (es)
AR (1) AR060890A1 (es)
AT (1) ATE545641T1 (es)
AU (1) AU2007251553A1 (es)
BR (1) BRPI0712400A2 (es)
CA (1) CA2647238A1 (es)
EA (1) EA200802214A1 (es)
EC (1) ECSP088905A (es)
IL (1) IL195218A0 (es)
MX (1) MX2008014500A (es)
NO (1) NO20083845L (es)
NZ (1) NZ573506A (es)
PE (2) PE20080068A1 (es)
TW (1) TW200815392A (es)
UA (1) UA94944C2 (es)
WO (1) WO2007132010A1 (es)
ZA (1) ZA200807581B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100144706A1 (en) * 2006-12-22 2010-06-10 Boehringer Ingelheim International Gmbh Compounds
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CA2718858A1 (en) * 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
CL2009000600A1 (es) * 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
PE20110294A1 (es) 2008-09-29 2011-05-26 Boehringer Ingelheim Int Compuestos heterociclicos como inhibidores de enzimas de senal especifica
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
US8933227B2 (en) * 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US20120107304A1 (en) * 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
JP5713367B2 (ja) 2010-06-04 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体
WO2012059932A1 (en) * 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
BR112013011600B1 (pt) 2010-11-10 2022-01-11 Genentech, Inc Derivados de pirazol aminopirimidina, seu uso e composição que os compreende
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
JP6275846B2 (ja) * 2013-12-05 2018-02-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 求電子性官能基を有するヘテロアリールピリドン及びアザ−ピリドン化合物
EP3736268A1 (en) * 2013-12-20 2020-11-11 Signal Pharmaceuticals, LLC Process for the preparation of substituted diaminopyrimidyl compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
KR100658489B1 (ko) 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Ｈｉｖ 복제를 억제하는 피리미딘
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
RS94703A (sr) 2001-05-29 2007-02-05 Schering Aktiengesellschaft, Cdk-inhibirajući pirimidini, njihovo dobijanje i primena kao sredstva za lečenje
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
ATE433447T1 (de) 2003-02-20 2009-06-15 Smithkline Beecham Corp Pyrimiidinverbindungen
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US20050113398A1 (en) * 2003-08-07 2005-05-26 Ankush Argade 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
WO2005118544A2 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors

Also Published As

Publication number Publication date
BRPI0712400A2 (pt) 2012-10-16
PE20120006A1 (es) 2012-02-02
KR20090018955A (ko) 2009-02-24
NO20083845L (no) 2008-12-11
EP2027107A1 (de) 2009-02-25
AR060890A1 (es) 2008-07-23
ZA200807581B (en) 2010-05-26
ECSP088905A (es) 2008-12-30
WO2007132010A1 (de) 2007-11-22
EP2357181A1 (de) 2011-08-17
TW200815392A (en) 2008-04-01
EP2027107B1 (de) 2012-02-15
CN101443325A (zh) 2009-05-27
EA200802214A1 (ru) 2009-06-30
UA94944C2 (ru) 2011-06-25
US8623887B2 (en) 2014-01-07
AU2007251553A1 (en) 2007-11-22
NZ573506A (en) 2011-12-22
ATE545641T1 (de) 2012-03-15
JP5247681B2 (ja) 2013-07-24
MX2008014500A (es) 2008-11-27
JP2009537485A (ja) 2009-10-29
CA2647238A1 (en) 2007-11-22
IL195218A0 (en) 2009-09-22
US20090163467A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
PE20080068A1 (es) Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
CO6150142A2 (es) Bezoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20120081A1 (es) Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
AR049784A1 (es) Derivados sustituidos de morfolina y tiomorfolina
PE20050907A1 (es) Pirimidinas sustituidas con sulfoximina como inhibidores de quinasa dependiente de ciclinas
PE20141409A1 (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
CY1118723T1 (el) Ενωσεις βενζοθειαζολιου και αζαβενζοθειαζολιου χρησιμες ως αναστολεiς κινασης
PE20161443A1 (es) Compuestos
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20050767A1 (es) Amino-benzazoles como inhibidores del receptor p2y1
AR066421A1 (es) Compuestos derivados de piridona
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
MEP8409A (en) Fused heterocyclic compound
PE20120798A1 (es) Potentes inhibidores de molecula pequena de autofagia
MY169179A (en) Novel piperidine compound or salt thereof
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20090372A1 (es) Derivados de indolinonas como inhibidores de quinasas especificas del ciclo celular
AR066606A1 (es) Compuestos de heteroarilamida pirimidona

Legal Events

Date Code Title Description
FC Refusal